

Joseph P Broderick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5900508/publications.pdf>

Version: 2024-02-01

85
papers

15,463
citations

81839

39
h-index

71651

76
g-index

86
all docs

86
docs citations

86
times ranked

13099
citing authors

#	ARTICLE	IF	CITATIONS
1	Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. <i>New England Journal of Medicine</i> , 2018, 378, 708-718.	13.9	3,433
2	The ABCs of Measuring Intracerebral Hemorrhage Volumes. <i>Stroke</i> , 1996, 27, 1304-1305.	1.0	1,740
3	Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke. <i>New England Journal of Medicine</i> , 2013, 368, 893-903.	13.9	1,666
4	Spontaneous Intracerebral Hemorrhage. <i>New England Journal of Medicine</i> , 2001, 344, 1450-1460.	13.9	1,509
5	Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. <i>Stroke</i> , 1999, 30, 905-915.	1.0	778
6	The Heidelberg Bleeding Classification. <i>Stroke</i> , 2015, 46, 2981-2986.	1.0	755
7	Unruptured intracranial aneurysms: epidemiology, natural history, management options, and familial screening. <i>Lancet Neurology</i> , The, 2014, 13, 393-404.	4.9	449
8	Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials. <i>Stroke</i> , 2017, 48, 2007-2012.	1.0	421
9	Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. <i>New England Journal of Medicine</i> , 2016, 374, 2313-2323.	13.9	352
10	The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. <i>International Journal of Stroke</i> , 2019, 14, 207-214.	2.9	304
11	Agreement and Variability in the Interpretation of Early CT Changes in Stroke Patients Qualifying for Intravenous rtPA Therapy. <i>Stroke</i> , 1999, 30, 1528-1533.	1.0	285
12	Ultra-early evaluation of intracerebral hemorrhage. <i>Journal of Neurosurgery</i> , 1990, 72, 195-199.	0.9	231
13	Individual Patient Data Subgroup Meta-Analysis of Surgery for Spontaneous Supratentorial Intracerebral Hemorrhage. <i>Stroke</i> , 2012, 43, 1496-1504.	1.0	222
14	Design and Validation of a Prehospital Scale to Predict Stroke Severity. <i>Stroke</i> , 2015, 46, 1508-1512.	1.0	218
15	Efficacy of Home-Based Telerehabilitation vs In-Clinic Therapy for Adults After Stroke. <i>JAMA Neurology</i> , 2019, 76, 1079.	4.5	213
16	Acute Stroke Imaging Research Roadmap II. <i>Stroke</i> , 2013, 44, 2628-2639.	1.0	192
17	Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 877-888.	6.3	178
18	An Analysis of Perioperative Surgical Mortality and Morbidity in the Asymptomatic Carotid Atherosclerosis Study. <i>Stroke</i> , 1996, 27, 2216-2224.	1.0	165

#	ARTICLE	IF	CITATIONS
19	Major Risk Factors for Aneurysmal Subarachnoid Hemorrhage in the Young Are Modifiable. <i>Stroke</i> , 2003, 34, 1375-1381.	1.0	159
20	Can a Subset of Intracerebral Hemorrhage Patients Benefit From Hemostatic Therapy With Recombinant Activated Factor VII?. <i>Stroke</i> , 2009, 40, 833-840.	1.0	148
21	Differential Effect of Baseline Computed Tomographic Angiography Collaterals on Clinical Outcome in Patients Enrolled in the Interventional Management of Stroke III Trial. <i>Stroke</i> , 2015, 46, 1239-1244.	1.0	121
22	Translational Stroke Research. <i>Stroke</i> , 2017, 48, 2632-2637.	1.0	108
23	Withdrawal of Antithrombotic Agents and Its Impact on Ischemic Stroke Occurrence. <i>Stroke</i> , 2011, 42, 2509-2514.	1.0	106
24	Stroke Recovery and Rehabilitation Research. <i>Stroke</i> , 2017, 48, 813-819.	1.0	98
25	Emergency Physicians. <i>Stroke</i> , 1995, 26, 2238-2241.	1.0	98
26	Evaluation of Interval Times From Onset to Reperfusion in Patients Undergoing Endovascular Therapy in the Interventional Management of Stroke III Trial. <i>Circulation</i> , 2014, 130, 265-272.	1.6	96
27	Acute Stroke Imaging Research Roadmap III Imaging Selection and Outcomes in Acute Stroke Reperfusion Clinical Trials. <i>Stroke</i> , 2016, 47, 1389-1398.	1.0	88
28	Rationale, Design, and Progress of the ENhanced Control of Hypertension ANd Thrombolysis Stroke Study (ENCHANTED) Trial: An International Multicenter 2 × 2 Quasi-Factorial Randomized Controlled Trial of Low- vs. Standard-Dose rt-PA and Early Intensive vs. Guideline-Recommended Blood Pressure Lowering in Patients with Acute Ischaemic Stroke Eligible for Thrombolysis Treatment. <i>International Journal of Stroke</i> , 2015, 10, 778-788.	2.9	82
29	Sex-specific stroke incidence over time in the Greater Cincinnati/Northern Kentucky Stroke Study. <i>Neurology</i> , 2017, 89, 990-996.	1.5	73
30	Effect of Recombinant Activated Coagulation Factor VII on Hemorrhage Expansion Among Patients With Spot Signâ€“Positive Acute Intracerebral Hemorrhage. <i>JAMA Neurology</i> , 2019, 76, 1493.	4.5	72
31	Basilar Occlusion Syndromes. <i>Neurohospitalist, The</i> , 2015, 5, 142-150.	0.3	61
32	Combined Approach to Lysis Utilizing Eptifibatid and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial. <i>Stroke</i> , 2015, 46, 2529-2533.	1.0	61
33	The Familial Intracranial Aneurysm (FIA) study protocol. <i>BMC Medical Genetics</i> , 2005, 6, 17.	2.1	60
34	Peripheral Monocyte Count Is Associated with Case Fatality after Intracerebral Hemorrhage. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, e107-e111.	0.7	59
35	Pediatric Stroke Rates Over 17 Years: Report From a Population-Based Study. <i>Journal of Child Neurology</i> , 2018, 33, 463-467.	0.7	47
36	Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3. <i>Stroke</i> , 2015, 46, 2325-2327.	1.0	44

#	ARTICLE	IF	CITATIONS
37	Effect of COVID-19 on Emergent Stroke Care. <i>Stroke</i> , 2020, 51, e2111-e2114.	1.0	44
38	Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy. <i>Stroke</i> , 2017, 48, 1877-1883.	1.0	42
39	Endovascular Therapy Is Effective and Safe for Patients With Severe Ischemic Stroke. <i>Stroke</i> , 2015, 46, 3416-3422.	1.0	41
40	Endovascular Therapy for Patients With Acute Ischemic Stroke During the COVID-19 Pandemic: A Proposed Algorithm. <i>Stroke</i> , 2020, 51, 1902-1909.	1.0	41
41	The Story of Intracerebral Hemorrhage. <i>Stroke</i> , 2021, 52, 1905-1914.	1.0	34
42	Transitions of Care for Stroke Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S190-2.	0.9	30
43	Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions. <i>Journal of NeuroInterventional Surgery</i> , 2015, 7, 795-802.	2.0	30
44	Endovascular Therapy of M2 Occlusion in IMS III: Role of M2 Segment Definition and Location on Clinical and Revascularization Outcomes. <i>American Journal of Neuroradiology</i> , 2017, 38, 84-89.	1.2	30
45	The National Institutes of Health StrokeNet. <i>Stroke</i> , 2016, 47, 301-303.	1.0	28
46	Estimated Impact of Emergency Medical Service Triage of Stroke Patients on Comprehensive Stroke Centers. <i>Stroke</i> , 2017, 48, 2164-2170.	1.0	28
47	Time to Angiographic Reperfusion in Acute Ischemic Stroke. <i>Stroke</i> , 2014, 45, 3625-3630.	1.0	26
48	Challenges of Acute Endovascular Stroke Trials. <i>Stroke</i> , 2014, 45, 3116-3122.	1.0	26
49	Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial. <i>Stroke</i> , 2015, 46, 1321-1327.	1.0	26
50	Imaging in StrokeNet. <i>Stroke</i> , 2015, 46, 2000-2006.	1.0	25
51	Recombinant Tissue-Type Plasminogen Activator Plus Eptifibatide Versus Recombinant Tissue-Type Plasminogen Activator Alone in Acute Ischemic Stroke. <i>Stroke</i> , 2015, 46, 461-464.	1.0	24
52	Endovascular Treatment in the DEFUSE 3 Study. <i>Stroke</i> , 2018, 49, 2000-2003.	1.0	23
53	Sleep for Stroke Management and Recovery Trial (Sleep SMART): Rationale and methods. <i>International Journal of Stroke</i> , 2020, 15, 923-929.	2.9	22
54	Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial. <i>International Journal of Stroke</i> , 2022, 17, 806-809.	2.9	21

#	ARTICLE	IF	CITATIONS
55	Variability in the Use of Intravenous Thrombolysis for Mild Stroke: Experience Across the SPOTRIAS Network. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2013, 22, 318-322.	0.7	20
56	Drivers of Costs Associated With Reperfusion Therapy in Acute Stroke. <i>Stroke</i> , 2014, 45, 1791-1798.	1.0	18
57	Relative Influence of Capillary Index Score, Revascularization, and Time on Stroke Outcomes From the Interventional Management of Stroke III Trial. <i>Stroke</i> , 2015, 46, 1590-1594.	1.0	16
58	Acute Stroke Imaging Research Roadmap IV: Imaging Selection and Outcomes in Acute Stroke Clinical Trials and Practice. <i>Stroke</i> , 2021, 52, 2723-2733.	1.0	15
59	Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study. <i>Stroke</i> , 2022, 53, 779-787.	1.0	14
60	National Institutes of Health StrokeNet During the Time of COVID-19 and Beyond. <i>Stroke</i> , 2020, 51, 2580-2586.	1.0	13
61	The Utility of Domain-Specific End Points in Acute Stroke Trials. <i>Stroke</i> , 2021, 52, 1154-1161.	1.0	13
62	Comparative effects of intensive-blood pressure versus standard-blood pressure-lowering treatment in patients with severe ischemic stroke in the ENCHANTED trial. <i>Journal of Hypertension</i> , 2021, 39, 280-285.	0.3	13
63	Coiling, clipping, or medical management of unruptured intracranial aneurysms: Time to randomize?. <i>Annals of Neurology</i> , 2000, 48, 5-6.	2.8	12
64	Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with) <i>Tj ETQq0 0 0 rgBE, Overlock 10 Tf 50 3</i>	1.0	11
65	To Treat or Not to Treat?. <i>Stroke</i> , 2018, 49, 1933-1938.	1.0	11
66	Logistics in Acute Stroke Management. <i>Drugs</i> , 1997, 54, 109-117.	4.9	10
67	Evolution of Practice During the Interventional Management of Stroke III Trial and Implications for Ongoing Trials. <i>Stroke</i> , 2014, 45, 3606-3611.	1.0	10
68	Heritability of circle of Willis variations in families with intracranial aneurysms. <i>PLoS ONE</i> , 2018, 13, e0191974.	1.1	9
69	Advances in Acute Stroke Treatment 2020. <i>Stroke</i> , 2021, 52, 729-734.	1.0	8
70	Advances in the treatment of hemorrhagic stroke: a possible new treatment.. <i>Cleveland Clinic Journal of Medicine</i> , 2005, 72, 341-344.	0.6	8
71	A Matched Comparison of Eptifibatid Plus rt-PA Versus rt-PA Alone in Acute Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, e313-e315.	0.7	7
72	Power of an Adaptive Trial Design for Endovascular Stroke Studies. <i>Stroke</i> , 2016, 47, 2931-2937.	1.0	7

#	ARTICLE	IF	CITATIONS
73	Thrombolysis in Mild Stroke. Stroke, 2021, 52, e586-e589.	1.0	5
74	Haemostatic treatment for intracerebral haemorrhage. Lancet, The, 2018, 391, 2081-2082.	6.3	3
75	Heritability of territory of ruptured and unruptured intracranial aneurysms in families. PLoS ONE, 2020, 15, e0236714.	1.1	3
76	American Stroke Association Stroke Council Update. Stroke, 2014, 45, e5-7.	1.0	2
77	Substance Use and Performance of Toxicology Screens in the Greater Cincinnati Northern Kentucky Stroke Study. Stroke, 2022, 53, 3082-3090.	1.0	2
78	Response to Letter by Morikawa. Stroke, 2008, 39, .	1.0	0
79	Response to Letter by Silva et al. Stroke, 2008, 39, .	1.0	0
80	Organizational Update. Stroke, 2014, 45, e104-5.	1.0	0
81	Organizational Update. Stroke, 2016, 47, e16-7.	1.0	0
82	Teaching Neuro <i>Images</i> : Crying thalamus. Neurology, 2017, 88, e72-e73.	1.5	0
83	Reply:. American Journal of Neuroradiology, 2017, 38, E44-E45.	1.2	0
84	Making the Right Call: Human Biases and Still Learning Machines. Stroke, 2021, 52, 3505-3506.	1.0	0
85	Advances in Stroke: Treatments-Acute. Stroke, 2022, 53, 999-1003.	1.0	0